Publications by authors named "T A Vyzantiadis"
Article Synopsis
- Progress has been made in treating childhood acute lymphoblastic leukemia (ALL), but relapsed or refractory cases remain difficult to treat.
- A 23-month-old girl with high-risk B-ALL experienced early isolation relapse and, after failing multiple treatments including chemotherapy and novel therapies, was given the off-label monoclonal antibody inotuzumab ozogamicin (InO).
- The use of InO led to a significant reduction in her minimal residual disease, allowing her to achieve remission and successfully undergo an allogeneic stem cell transplant from a family donor.
This case report outlines the diagnostic and therapeutic challenges encountered in a man in his 70s suffering from knee septic arthritis caused by It is the second published case in the literature with osteoarticular infection from and the first one in the last 40 years. Following knee arthroscopy, the patient experienced persistent pain, swelling and discomfort, prompting further investigation. Postoperative knee cultures were negative for infection, but symptoms were not ameliorated.
View Article and Find Full Text PDFCandida auris is an emerging fungal pathogen associated with multi-drug resistance rates and widespread outbreaks in hospitals and healthcare units worldwide. Sequencing studies have revealed that different clonal lineages of the fungus seem to be prevalent among distinct geographical sites. The first case of C.
View Article and Find Full Text PDFRisk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis.
Cancers (Basel)
July 2023
(1) Background: Autologous, allogeneic hematopoietic cell transplantation (HCT) and other cellular therapies, including CAR T cell and gene therapy, constitute a cornerstone in the management of various benign and malignant hematological disorders. Invasive fungal infections (IFD) remain a significant cause of morbidity and mortality in HCT recipients. Therefore, we investigated the prevalence and risk factors of IFD following HCT and other cellular therapies in an era of novel antifungal prophylaxis.
View Article and Find Full Text PDFArticle Synopsis
- * The most common forms of the infection were rhinocerebral (51.8%), cutaneous (32.4%), and pulmonary (11.1%), with significant underlying conditions including hematologic malignancies, diabetes mellitus, and other immunodeficiencies, along with some cases in immunocompetent individuals due to trauma.
- * Antifungal treatment typically involved liposomal amphotericin B, and although the mortality rate was high